Vivos Therapeutics Faces Nasdaq Delisting Concerns
Ticker: VVOS · Form: 8-K · Filed: May 17, 2024 · CIK: 1716166
| Field | Detail |
|---|---|
| Company | Vivos Therapeutics, Inc. (VVOS) |
| Form Type | 8-K |
| Filed Date | May 17, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $2.5 million |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, sec-filing
TL;DR
Vivos might get kicked off Nasdaq - big trouble ahead.
AI Summary
Vivos Therapeutics, Inc. filed an 8-K on May 17, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is facing potential delisting from the Nasdaq Capital Market due to not meeting certain continued listing standards.
Why It Matters
This filing indicates potential delisting from a major stock exchange, which could significantly impact the company's liquidity, investor confidence, and stock price.
Risk Assessment
Risk Level: high — The company has received a notice of delisting, indicating it is not meeting continued listing standards, which poses a significant threat to its stock market presence.
Key Players & Entities
- Vivos Therapeutics, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Exchange where the company is listed
- May 17, 2024 (date) — Filing date of the 8-K
- May 16, 2024 (date) — Earliest event reported date
FAQ
What specific continued listing rule(s) has Vivos Therapeutics failed to meet?
The filing does not specify the exact rule(s) violated, only that the company received a notice of delisting or failure to satisfy a continued listing rule or standard.
What is the date of the notice of delisting or failure to satisfy a continued listing rule?
The earliest event reported date is May 16, 2024, and the filing date is May 17, 2024.
What exchange is Vivos Therapeutics potentially being delisted from?
The company is potentially being delisted from the Nasdaq Capital Market.
What is Vivos Therapeutics' principal executive office address?
The address is 7921 Southpark Plaza, Suite 210, Littleton, Colorado 80120.
What is the company's IRS Employer Identification No.?
The IRS Employer Identification No. is 81-3224056.
Filing Stats: 1,028 words · 4 min read · ~3 pages · Grade level 14.5 · Accepted 2024-05-17 16:43:05
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The Nasdaq Stock Mar
- $2.5 million — quires stockholders' equity of at least $2.5 million (the " Minimum Stockholders' Equity Req
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-24-020446.txt ( ) — 213KB
- vvos-20240517.xsd (EX-101.SCH) — 3KB
- vvos-20240517_lab.xml (EX-101.LAB) — 33KB
- vvos-20240517_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
forward-looking statements as circumstances change, except as required by securities laws
forward-looking statements as circumstances change, except as required by securities laws. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIVOS THERPEUTICS, INC. Dated: May 17, 2024 By: /s/ Bradford Amman Bradford Amman Chief Financial Officer